Overview Financials News + Filings IR Vault Key Docs Charts Ownership Insiders
All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Director comp.
Appointed director
CC transcript
Asset disposition
Quarterly results
Appointed CFO
|
|
ImmunoGen, Inc. (IMGN)
|
Create: Alert |
All | News | Filings
| Date Filed | Type | Description |
| 10/02/2023 |
4
| Thackray Helen M. (Director) has filed a Form 4 on ImmunoGen, Inc.|
Txns:
| Granted 472 shares
@ $15.87, valued at
$7.5k
|
|
| 10/02/2023 |
4
| Arbuckle Stuart A (Director) has filed a Form 4 on ImmunoGen, Inc.|
Txns:
| Granted 827 shares
@ $15.87, valued at
$13.1k
|
|
| 10/02/2023 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 09/26/2023 |
4
| MITCHELL DEAN J (Director) has filed a Form 4 on ImmunoGen, Inc.|
Txns:
| Exercised 10,000 options to buy
@ $14.7, valued at
$147k
|
|
| 08/25/2023 |
144
| Form 144 - Report of proposed sale of securities: |
| 08/24/2023 |
144
| Form 144 - Report of proposed sale of securities: |
| 08/23/2023 |
144
| Form 144 - Report of proposed sale of securities: |
| 08/22/2023 |
144
| Form 144 - Report of proposed sale of securities: |
| 08/21/2023 |
144
| Form 144 - Report of proposed sale of securities: |
| 08/18/2023 |
144
| Form 144 - Report of proposed sale of securities: |
| 08/17/2023 |
144
| Form 144 - Report of proposed sale of securities: |
| 08/16/2023 |
144
| Form 144 - Report of proposed sale of securities: |
| 08/15/2023 |
144
| Form 144 - Report of proposed sale of securities: |
| 08/14/2023 |
144
| Form 144 - Report of proposed sale of securities: |
| 08/11/2023 |
4
| Coen Stacy Ann (SVP & CHIEF BUSINESS OFFICER) has filed a Form 4 on ImmunoGen, Inc.|
Txns:
| Sold 100,210 shares
@ $14.2, valued at
$1.4M
Exercised 100,210 options to buy
@ $4.92, valued at
$493k
|
|
| 08/09/2023 |
144
| Form 144 - Report of proposed sale of securities: |
| 08/04/2023 |
4
| Coen Stacy Ann (SVP & CHIEF BUSINESS OFFICER) has filed a Form 4 on ImmunoGen, Inc.|
Txns:
| Sold 4,255 shares
@ $18.12, valued at
$77.1k
Sold 80,326 shares
@ $17.05, valued at
$1.4M
Exercised 4,255 options to buy
@ $4.92, valued at
$20.9k
Exercised 80,326 options to buy
@ $4.92, valued at
$395.2k
|
|
| 08/04/2023 |
4
| Enyedy Mark J (CEO) has filed a Form 4 on ImmunoGen, Inc.|
Txns:
| Sold 986,521 shares
@ $17.45, valued at
$17.2M
Sold 8,636 shares
@ $18.15, valued at
$156.7k
Sold 1,020,000 shares
@ $16.61, valued at
$16.9M
Sold 992,397 shares
@ $16.96, valued at
$16.8M
Exercised 995,157 options to buy
@ $4.55, valued at
$4.5M
Exercised 2,760 options to buy
@ $5.25, valued at
$14.5k
Exercised 831,147 options to buy
@ $4.55, valued at
$3.8M
Exercised 186,093 options to buy
@ $4.55, valued at
$846.7k
Exercised 300,000 options to buy
@ $5.65, valued at
$1.7M
Exercised 782,240 options to buy
@ $5.25, valued at
$4.1M
Exercised 21,978 options to buy
@ $4.55, valued at
$100k
|
|
| 08/04/2023 |
4
| Lentini Renee (PRIN. FIN & ACCTG. OFF.) has filed a Form 4 on ImmunoGen, Inc.|
Txns:
| Sold 148,277 shares
@ $17.55, valued at
$2.6M
Exercised 18,218 options to buy
@ $5.25, valued at
$95.6k
Exercised 40,348 options to buy
@ $2.31, valued at
$93.2k
Exercised 36,053 options to buy
@ $4.55, valued at
$164k
Exercised 23,751 options to buy
@ $6.98, valued at
$165.8k
Exercised 29,907 options to buy
@ $5.32, valued at
$159.1k
Exercised 28,652 options to buy
@ $2.31, valued at
$66.2k
Exercised 6,000 options to buy
@ $2.47, valued at
$14.8k
Exercised 16,381 options to buy
@ $2.68, valued at
$43.9k
|
|
| 08/04/2023 |
144
| Form 144 - Report of proposed sale of securities: |
| 08/04/2023 |
144
| Form 144 - Report of proposed sale of securities: |
| 08/03/2023 |
144
| Form 144 - Report of proposed sale of securities: |
| 08/02/2023 |
144
| Form 144 - Report of proposed sale of securities: |
| 08/02/2023 |
144
| Form 144 - Report of proposed sale of securities: |
| 08/02/2023 |
144
| Form 144 - Report of proposed sale of securities: |
| 07/31/2023 |
10-Q
| Quarterly Report for the period ended June 30, 2023 |
| 07/31/2023 |
8-K
| Quarterly results |
| 07/05/2023 |
4
| Enyedy Mark J (CEO) has filed a Form 4 on ImmunoGen, Inc.|
Txns:
| Granted 5,241 shares
@ $4.05, valued at
$21.2k
|
|
| 07/05/2023 |
4
| Wingrove Theresa (SVP OF REGULATORY AFFAIRS) has filed a Form 4 on ImmunoGen, Inc.|
Txns:
| Granted 2,811 shares
@ $4.05, valued at
$11.4k
|
|
| 07/05/2023 |
4
| Berkenblit Anna (SVP & CHIEF MEDICAL OFFICER) has filed a Form 4 on ImmunoGen, Inc.|
Txns:
| Granted 3,264 shares
@ $4.05, valued at
$13.2k
|
|
| 07/05/2023 |
4
| Coen Stacy Ann (SVP & CHIEF BUSINESS OFFICER) has filed a Form 4 on ImmunoGen, Inc.|
Txns:
| Granted 3,792 shares
@ $4.05, valued at
$15.4k
|
|
| 07/05/2023 |
4
| Lentini Renee (V.P.-FIN., PRIN. ACCTG. OFF.) has filed a Form 4 on ImmunoGen, Inc.|
Txns:
| Granted 3,195 shares
@ $4.05, valued at
$12.9k
|
|
| 07/05/2023 |
4
| Arbuckle Stuart A (Director) has filed a Form 4 on ImmunoGen, Inc.|
Txns:
| Granted 695 shares
@ $18.87, valued at
$13.1k
|
|
| 07/05/2023 |
4
| Goldberg Mark Alan (Director) has filed a Form 4 on ImmunoGen, Inc.|
Txns:
| Granted 894 shares
@ $18.87, valued at
$16.9k
|
|
|
|
|